

09/802376

FILE 'REGISTRY' ENTERED AT 11:56:14 ON 01 NOV 2004
L1 102 S TGA CTGTGAACGTTTCGAGATGA/SQSN

FILE 'CAPLUS' ENTERED AT 11:57:03 ON 01 NOV 2004
L2 76 S L1
L3 36 S L2 AND (IMMUNOMODULAT? OR IMMUN?(3A)MODULAT?)

L3 ANSWER 1 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN
ED Entered STN: 15 Jul 2004
ACCESSION NUMBER: 2004:566552 CAPLUS
DOCUMENT NUMBER: 141:99693
TITLE: Immunostimulatory oligonucleotides, sequences, and
methods of using the same
INVENTOR(S): Dina, Dino; Fearon, Karen L.; Marshall, Jason
PATENT ASSIGNEE(S): Dynavax Technologies, USA
SOURCE: PCT Int. Appl., 119 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058179	A2	20040715	WO 2003-US41001	20031218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2002-436122P	P 20021223
			US 2003-447885P	P 20030213
			US 2003-467546P	P 20030501

AB The invention provides **immunomodulatory** polynucleotides (IMPs) and methods for **immunomodulation** of individuals using the **immunomodulatory** polynucleotides. In accordance with the present invention, the IMP contains at least one palindromic sequence of at least 8 bases in length containing at least one CG dinucleotide. The IMP also contains at least one TCG trinucleotide sequence at or near the 5'-end of the polynucleotide. In some instances, the palindromic sequence and the 5'-TCG are separated by 0, 1, 2, 3, 4 or 5 bases in the IMP. In some instances the palindromic sequence includes all or part of the 5'-TCG. Claimed is an **immunomodulatory** polynucleotide, comprising: (a) 5'-Nx(TCG(Nq))yNw(X1X2CGX2'X1'(CG)p)z (SEQ ID NO: 156) wherein N are nucleosides, x = 0-3, yr = 1-4, w = -2, -1, 0, 1 or 2, p = 0 or 1, q = 0, 1 or 2, and z = 1-20, X1 and X1', X2 and X2' are self-complimentary nucleosides, and wherein the 5' T of the (TCG(Nq))y sequence is 0-3 bases from the 5' end of the polynucleotide; and (b) a palindromic sequence at least 8 bases in length wherein the palindromic sequence comprises the first (X1X2CGX2'X,') of the (X1X2CGX2'X1'(CG)p)z sequences.

IT 721175-12-8

RL: PRP (Properties)

(unclaimed nucleotide sequence; immunostimulatory oligonucleotides, sequences, and methods of using the same)

L3 ANSWER 2 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN

ED Entered STN: 09 Jul 2004

ACCESSION NUMBER: 2004:550731 CAPLUS

DOCUMENT NUMBER: 141:99687

TITLE: Chimeric **immunomodulatory** compounds and methods of using the same

INVENTOR(S): Fearon, Karen L.; Dina, Dino; Tuck, Stephen F.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 132 pp., Cont.-in-part of U.S. Pat. Appl. 2003 225,016.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004132677	A1	20040708	US 2003-623371	20030718
US 2003175731	A1	20030918	US 2002-176883	20020621
US 2003199466	A1	20031023	US 2002-177826	20020621
US 2003225016	A1	20031204	US 2002-328578	20021223
PRIORITY APPLN. INFO.:			US 2001-299883P	P 20010621
			US 2002-375253P	P 20020423
			US 2002-176883	A2 20020621
			US 2002-177826	A2 20020621
			US 2002-328578	A2 20021223

AB The invention provides chimeric **immunomodulatory** compds. (CICs) and methods for **immunomodulation** of individuals using the **immunomodulatory** compds. **Immunomodulation** is accomplished by administration of **immunomodulatory** polynucleotide/microcarrier (IMP/MC) complexes. The IMP/MC complexes may be covalently or non-covalently bound, and feature a polynucleotide comprising at least one immunostimulatory sequence bound to a nonbiodegradable microcarrier or nanocarrier. Claimed is a CIC that stimulates production of IFN- α from human peripheral blood mononuclear cells, and comprises at least three nucleic acid moieties, at least one of which comprises a sequence 5'-TCGY, where Y is selected from the group consisting of XCGX, XTCG, XXCG, and CGXX, where X is any nucleotide, and at least one nonnucleic acid spacer moiety.

IT 503638-07-1

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(chimeric **immunomodulatory** compds. (CICs) and methods of using same)

IT 718384-16-8 718384-37-3

RL: PRP (Properties)

(unclaimed nucleotide sequence; chimeric **immunomodulatory** compds. and methods of using the same)

L3 ANSWER 3 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN

09/802376

ED Entered STN: 25 Jun 2004
ACCESSION NUMBER: 2004:513488 CAPLUS
DOCUMENT NUMBER: 141:70229
TITLE: Compositions comprising truncated flavivirus envelope glycoproteins and adjuvant for use as recombinant vaccine against flavivirus infection
INVENTOR(S): Lieberman, Michael
PATENT ASSIGNEE(S): Hawaii Biotech, Inc., USA
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004052293	A2	20040624	WO 2003-US38914	20031208
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004213808	A1	20041028	US 2003-730776	20031208
PRIORITY APPLN. INFO.:			US 2002-432865P	P 20021211
			US 2003-493312P	P 20030806

AB An immunogenic composition is described which preferably contains recombinantly produced forms of truncated flavivirus envelope glycoproteins and an adjuvant. The disclosed immunogenic compns. can further comprise a recombinantly produced non-structural (non-envelope) flavivirus protein. The adjuvant typically comprises a saponin preferably derived from the Quillaja saponaria tree or a derivative thereof. The adjuvant can also comprise an oligodeoxyribonucleotide preferably containing specific sequences of nucleotides described herein. A pharmaceutically acceptable vehicle may also be included in the immunogenic composition

IT **711385-52-3**
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. comprising truncated flavivirus envelope glycoproteins and adjuvant for use as recombinant vaccine against flavivirus infection)

L3 ANSWER 4 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN
ED Entered STN: 22 Feb 2004
ACCESSION NUMBER: 2004:142919 CAPLUS
DOCUMENT NUMBER: 140:198064
TITLE: Particulate immunostimulant
INVENTOR(S): Van Nest, Gary; Tuck, Stephen
PATENT ASSIGNEE(S): Dynavax Technologies Corporation, USA

Searcher : Shears 571-272-2528

09/802376

SOURCE: PCT Int. Appl., 90 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014322	A2	20040219	WO 2003-US25415	20030812
WO 2004014322	A3	20040708		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2002-402968P P 20020812

AB The authors disclose **immunomodulatory** compns. which comprise a cationic condensing agent, an **immunomodulatory** compound, and a stabilizing agent. The compns. of the invention typically form particles which have increased **immunomodulatory** activity as compared to **immunomodulatory** compds. not formulated in the compns. of the invention. Also provided are methods of making the compns. and methods for therapeutic use of the compns. In one example, interferon- γ release by human mononuclear cells was shown to be enhanced by the combination of CpG oligonucleotide, polymyxin B, and Tween-80.

IT **661771-84-2**

RL: PRP (Properties)
 (unclaimed sequence; particulate immunostimulant)

L3 ANSWER 5 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN

ED Entered STN: 26 Jan 2004

ACCESSION NUMBER: 2004:60254 CAPLUS

DOCUMENT NUMBER: 140:139452

TITLE: Combination therapies with FTC and an **immunomodulator** for the treatment of hepatitis B virus infection

INVENTOR(S): Furman, Philip A.

PATENT ASSIGNEE(S): Triangle Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 112 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004006848	A2	20040122	WO 2003-US21929	20030715
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

Searcher : Shears 571-272-2528

09/802376

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-396117P P 20020715

AB A method, use and composition for the treatment of a host infected with hepatitis B is provided that includes administering β -L-FTC or its pharmaceutically acceptable salt or prodrug in combination or alternation with an **immunomodulator**, or in particular, an immunostimulating agent to achieve minimal or no detectable viral load in the host, which may be a human.

IT 647920-72-7

RL: PRP (Properties)

(unclaimed sequence; combination therapies with FTC and an **immunomodulator** for the treatment of hepatitis B virus infection)

L3 ANSWER 6 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN

ED Entered STN: 18 Jan 2004

ACCESSION NUMBER: 2004:41111 CAPLUS

DOCUMENT NUMBER: 140:105233

TITLE: Methods of preventing and treating respiratory viral infection using **immunomodulatory** polynucleotide sequences

INVENTOR(S): Van Nest, Gary

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. Pat. Appl. 2001 46,967.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004009942	A1	20040115	US 2003-426237	20030429
US 2001046967	A1	20011129	US 2001-802686	20010309
PRIORITY APPLN. INFO.:			US 2000-188583P	P 20000310
			US 2001-802686	A2 20010309

AB The invention provides methods of preventing and/or treating infection by a respiratory virus such as respiratory syncytial virus (RSV) and SARS-associated coronavirus, particularly reducing infection and/or one or more symptoms of respiratory virus infection. A polynucleotide comprising an immunostimulatory sequence (an "ISS") is administered to an individual which is at risk of being exposed to a respiratory virus, has been exposed to a respiratory virus or is infected with a respiratory virus. The ISS is administered without any antigens of the respiratory virus. Administration of the ISS results in reduced incidence and/or severity of one or more symptoms of respiratory virus infection. Nasal administration

Searcher : Shears 571-272-2528

of ISS (5'-TGACTGTGAACGTTTCGAGATGA-3') reduced RSV viral titer in infected tissue compared to PBS or non-ISS administration. A first administration of ISS on the day of infection was not effective, while administration before infection (in this experiment, 3 days) was effective at reducing viral titers.

IT 645428-19-9 646074-82-0

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(immunomodulatory polynucleotide sequences for preventing and treating respiratory viral infection)

L3 ANSWER 7 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN

ED Entered STN: 05 Dec 2003

ACCESSION NUMBER: 2003:950038 CAPLUS

DOCUMENT NUMBER: 140:26897

TITLE: Chimeric immunomodulatory compounds comprising two or more nucleic acid moieties and non-nucleic acid spacer

INVENTOR(S): Fearon, Karen L.; Dina, Dino; Tuck, Stephen F.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 96 pp., Cont.-in-part of U.S. Ser. No. 176,883.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003225016	A1	20031204	US 2002-328578	20021223
US 2003175731	A1	20030918	US 2002-176883	20020621
US 2003199466	A1	20031023	US 2002-177826	20020621
US 2004132677	A1	20040708	US 2003-623371	20030718
PRIORITY APPLN. INFO.:			US 2001-299883P	P 20010621
			US 2002-375253P	P 20020423
			US 2002-176883	A2 20020621
			US 2002-177826	A2 20020621
			US 2002-328578	A2 20021223

AB The invention provides immunomodulatory compds. and methods for immunomodulation of individuals using the immunomodulatory compds. The immunomodulatory compds. comprise two or more nucleic acid moieties and a non-nucleic acid spacer moiety. The nucleic acid contains e.g. 5'-CG-3', 5'-TCG-3', 5'-TCGA-3', 5'-TCGACGT-3', or 5'-TCGACGA-3'; and the non-nucleic acid is an oligoethylene glycol such as hexaethylene glycol. The chimeric compds. are incorporated into endotoxin-free compns. comprising antigen, pharmaceutically acceptable excipient, and optionally a cationic microsphere for modulating immune response.

IT 628357-70-0P 631925-82-1P 631926-19-7P
632370-48-0P

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(chimeric immunomodulatory compds. comprising two or more

nucleic acid moieties and non-nucleic acid spacer)
 IT **630432-24-5**
 RL: PRP (Properties)
 (unclaimed sequence; chimeric **immunomodulatory** compds.
 comprising two or more nucleic acid moieties and non-nucleic acid
 spacer)

L3 ANSWER 8 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN

ED Entered STN: 11 Jul 2003

ACCESSION NUMBER: 2003:532336 CAPLUS

DOCUMENT NUMBER: 139:79154

TITLE: Use of **immunomodulatory** CpG
 oligodeoxynucleotides for treatment of inflammatory
 bowel disease and other gastrointestinal inflammation

INVENTOR(S): Raz, Eyal; Rachmilewitz, Daniel

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 30 pp., Cont.-in-part of U.S.
 Ser. No. 791,500.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003130217	A1	20030710	US 2002-219143	20020813
US 2002042387	A1	20020411	US 2001-791500	20010222
US 6613751	B2	20030902		
US 2003176389	A1	20030918	US 2003-412151	20030411
PRIORITY APPLN. INFO.:			US 2000-184256P	P 20000223
			US 2001-791500	A2 20010222

AB The invention provides a method for ameliorating gastrointestinal
 inflammation, particularly chronic gastrointestinal inflammation such as
 inflammatory bowel disease (IBD), in a subject. In one embodiment, the
 method comprises administering an **immunomodulatory** nucleic acid
 to a subject suffering from or susceptible to gastrointestinal
 inflammation.

IT **556163-51-0**

RL: PRP (Properties)

(unclaimed nucleotide sequence; use of **immunomodulatory** CpG
 oligodeoxynucleotides for treatment of inflammatory bowel disease and
 other gastrointestinal inflammation)

L3 ANSWER 9 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN

ED Entered STN: 09 Jul 2003

ACCESSION NUMBER: 2003:524031 CAPLUS

DOCUMENT NUMBER: 139:83965

TITLE: Immunostimulatory oligonucleotides and antigens for
 screening immunostimulants and for treating cancer,
 allergy and infections

INVENTOR(S): Raz, Eyal; Roman, Mark; Dina, Dino

PATENT ASSIGNEE(S): Dynavax Technologies Corporation, USA

SOURCE: U.S., 44 pp., Cont.-in-part of U.S. Ser. No. 92,329,
 abandoned.

CODEN: USXXAM

09/802376

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6589940	B1	20030708	US 1999-296477	19990422
EP 1374894	A2	20040102	EP 2003-20257	19980605
EP 1374894	A3	20040922		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
US 2002086839	A1	20020704	US 2001-770943	20010125
US 2004006034	A1	20040108	US 2003-413504	20030411
PRIORITY APPLN. INFO.:				
			US 1997-48793P	P 19970606
			US 1998-92329	B2 19980605
			EP 1998-926311	A3 19980605
			US 1998-92314	A1 19980605
			US 1999-296477	A1 19990422

AB The invention relates to immunostimulatory oligonucleotide compns. These oligonucleotides comprise an immunostimulatory octanucleotide sequence. These oligonucleotides can be administered in conjunction with an immunostimulatory peptide or antigen. Methods for **modulating** an **immune** response upon administration of the oligonucleotide are also disclosed. In addition, an in vitro screening method to identify oligonucleotides with immunostimulatory activity is provided.

IT **552901-87-8D**, phosphorothioate or phosphate derivs.
552901-88-9D, phosphorothioate or phosphate derivs.
554461-70-0D, phosphorothioate or phosphate derivs.
 RL: ARG (Analytical reagent use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (immunostimulatory oligonucleotides and antigens for screening immunostimulants and for treating cancer, allergy and infections)

REFERENCE COUNT: 240 THERE ARE 240 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN
 ED Entered STN: 25 Apr 2003

ACCESSION NUMBER: 2003:319450 CAPLUS

DOCUMENT NUMBER: 138:331689

TITLE: Polarization of the helper T-cell response with immunostimulatory nucleic acid

INVENTOR(S): Raz, Eyal; Broide, David

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 56 pp., Cont.-in-part of U.S. Ser. No. 235,742.
 CODEN: USXXCO

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 12
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003078223	A1	20030424	US 2002-99512	20020315

Searcher : Shears 571-272-2528

09/802376

US 6498148 B1 20021224 US 1999-235742 19990121
AU 759590 B2 20030417 AU 2001-23162 20010221
US 2003203861 A1 20031030 US 2001-947209 20010904
US 2003109469 A1 20030612 US 2002-99379 20020614
US 2003092663 A1 20030515 US 2002-229208 20020826
PRIORITY APPLN. INFO.: US 1996-593554 B1 19960130
US 1997-927120 B2 19970905
US 1999-235742 A2 19990121
US 1999-265191 A2 19990310
US 2001-276865P P 20010316
US 1993-112440 B2 19930826
US 1995-446691 B2 19950607
AU 1997-18418 A3 19970128

AB The authors disclose methods of maintaining suppression of a Th2 immune response and increasing a Th1 immune response in an individual. The methods generally involve administering to an individual an effective amount of an immunostimulatory nucleic acid. In one example, administration of an immunostimulatory oligonucleotide suppresses pulmonary eosinophil accumulation in a Th2-driven model of asthma. Amelioration of the immunol. markers associated with asthma pathol. was shown to coincide with polarization to a type 1 helper T-cell response.

IT 515181-95-0

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(immunomodulatory and therapeutic application of CpG-containing oligonucleotides)

L3 ANSWER 11 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN

ED Entered STN: 28 Mar 2003

ACCESSION NUMBER: 2003:241873 CAPLUS

DOCUMENT NUMBER: 138:292710

TITLE: Immunomodulatory formulations and methods for use thereof

INVENTOR(S): Van Nest, Gary; Tuck, Stephen; Fearon, Karen L.; Dina, Dino

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 30 pp., Cont.-in-part of U.S. Ser. No. 802,376.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003059773	A1	20030327	US 2001-927884	20010810
US 2002055477	A1	20020509	US 2001-802376	20010309
WO 2003015816	A1	20030227	WO 2001-US25364	20010813

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

Searcher : Shears 571-272-2528

09/802376

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1414490 A1 20040506 EP 2001-959743 20010813
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
PRIORITY APPLN. INFO.: US 2000-188557P P 20000310
US 2001-802376 A2 20010309
US 2001-927422 A2 20010810
US 2001-927884 A2 20010810
WO 2001-US25364 W 20010813

OTHER SOURCE(S): MARPAT 138:292710

AB The invention provides new compns. and methods for
immunomodulation of individuals. **Immunomodulation** is
accomplished by administration of **immunomodulatory**
polynucleotide/microcarrier (IMP/MC) complexes. The IMP/MC complexes may
be covalently or non-covalently bound, and feature a polynucleotide
comprising at least one immunostimulatory sequence bound to a
nonbiodegradable microcarrier or nanocarrier.

IT 503638-07-1

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical
process); PRP (Properties); PYP (Physical process); THU (Therapeutic use);
BIOL (Biological study); PROC (Process); USES (Uses)
(**immunomodulatory** polynucleotide/microcarrier complex
formulations and methods for use thereof)

L3 ANSWER 12 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN

ED Entered STN: 21 Feb 2003

ACCESSION NUMBER: 2003:133429 CAPLUS

DOCUMENT NUMBER: 138:210275

TITLE: **Immunomodulatory** compositions, formulations,
and methods for use thereof

INVENTOR(S): Fearon, Karen L.; Dina, Dino

PATENT ASSIGNEE(S): Dynavax Technologies Corporation, USA

SOURCE: PCT Int. Appl., 79 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003014316	A2	20030220	WO 2002-US25123	20020807
WO 2003014316	A3	20040311		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

Searcher : Shears 571-272-2528

09/802376

US 2003133988 A1 20030717 US 2002-214799 20020807
EP 1420829 A2 20040526 EP 2002-761284 20020807
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
PRIORITY APPLN. INFO.: US 2001-310743P P 20010807
US 2001-335263P P 20011025
WO 2002-US25123 W 20020807

OTHER SOURCE(S): MARPAT 138:210275

AB The invention provides new compns. and methods for
immunomodulation of individuals. **Immunomodulation** is
accomplished by administration of **immunomodulatory**
polynucleotide/microcarrier (IMO/MC) complexes comprising 3-6mer
immunomodulatory oligonucleotides. The IMO/MC complexes may be
covalently or non-covalently bound. Also provided are
immunomodulatory compns. comprising a 3-6mer IMO encapsulated in
an MC.

IT 499810-15-0

RL: PRP (Properties)

(unclaimed sequence; **immunomodulatory** compns., formulations,
and methods for use thereof)

L3 ANSWER 13 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN

ED Entered STN: 31 Jan 2003

ACCESSION NUMBER: 2003:77543 CAPLUS

DOCUMENT NUMBER: 138:142468

TITLE: Biodegradable **immunomodulatory** formulations
containing polynucleotides

INVENTOR(S): Van Nest, Gary; Tuck, Stephen; Fearon, Karen L.; Dina,
Dino

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 35 pp., Cont.-in-part of U.S.
Ser. No. 802,359.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003022852	A1	20030130	US 2001-927422	20010810
US 2003129251	A1	20030710	US 2001-802359	20010309
WO 2003015816	A1	20030227	WO 2001-US25364	20010813
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1414490	A1	20040506	EP 2001-959743	20010813
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRIORITY APPLN. INFO.:			US 2000-188303P	P 20000310

Searcher : Shears 571-272-2528

09/802376

US 2001-802359 A2 20010309
US 2001-927422 A2 20010810
US 2001-927884 A2 20010810
WO 2001-US25364 W 20010813

AB The invention provides new compns. and methods for **immunomodulation** of individuals. **Immunomodulation** is accomplished by administration of **immunomodulatory** polynucleotide/microcarrier (IMP/MC) complexes. The IMP/MC complexes may be covalently or non-covalently bound, and feature a polynucleotide comprising at least one immunostimulatory sequence bound to a biodegradable microcarrier or noncarrier.

IT **491894-86-1 492479-51-3**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(biodegradable **immunomodulatory** formulations containing polynucleotide/microcarrier and optionally allergen)

L3 ANSWER 14 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN

ED Entered STN: 05 Jan 2003

ACCESSION NUMBER: 2003:6160 CAPLUS

DOCUMENT NUMBER: 138:88635

TITLE: Chimeric **immunomodulatory** compounds comprising nucleic acids linked through dendrimer or polysaccharide spacer and antigen for treating allergy, infection or cancer

INVENTOR(S): Fearon, Karen L.; Dina, Dino; Tuck, Stephen F.

PATENT ASSIGNEE(S): Dynavax Technologies Corporation, USA

SOURCE: PCT Int. Appl., 224 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000922	A2	20030103	WO 2002-US20025	20020621
WO 2003000922	A3	20031023		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1404873	A2	20040407	EP 2002-744589	20020621
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			

PRIORITY APPLN. INFO.: US 2001-299883P P 20010621
US 2002-375253P P 20020423
WO 2002-US20025 W 20020621

AB The invention provides **immunomodulatory** compds. (CIC) and methods for **immunomodulation** of individuals using the

Searcher : Shears 571-272-2528

immunomodulatory compds. The CIC comprises one or more nucleic acid moieties and one or more non-nucleic acid moieties such as dendrimer, polysaccharide, and crosslinked polysaccharide through phosphodiester, phosphorothioate ester, phosphorodithioate ester, and other linkages. The CIC is capable of stimulating production of interferon γ and α by human peripheral blood mononuclear cells, as well as human B cell proliferation. Endotoxin-free compns. comprising the CIC covalently or non-covalently conjugated with antigen and cationic microsphere are useful for treating disorders associated with IgE or Th2-type immune response such as allergy, asthma, infection, viral infection, idiopathic pulmonary fibrosis, and cancer.

IT 482661-42-7P 482663-60-5P 483382-52-1P

483382-54-3P

RL: PAC (Pharmacological activity); PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(chimeric **immunomodulatory** compds. comprising nucleic acids linked through dendrimer or polysaccharide spacer and antigen for treating allergy, infection or cancer)

IT 479469-88-0P

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(chimeric **immunomodulatory** compds. comprising nucleic acids linked through dendrimer or polysaccharide spacer and antigen for treating allergy, infection or cancer)

IT 482386-35-6 482387-18-8

RL: PRP (Properties)

(unclaimed nucleotide sequence; chimeric **immunomodulatory** compds. comprising nucleic acids linked through dendrimer or polysaccharide spacer and antigen for treating allergy, infection or cancer)

L3 ANSWER 15 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN

ED Entered STN: 27 Sep 2002

ACCESSION NUMBER: 2002:736377 CAPLUS

DOCUMENT NUMBER: 137:273193

TITLE: Nucleic acid compositions and methods for **modulating** an **immune** response

INVENTOR(S): Broide, David H.; Raz, Eyal

PATENT ASSIGNEE(S): The Regents of the University of California, USA

SOURCE: PCT Int. Appl., 98 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 12

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002074922	A2	20020926	WO 2002-US8207	20020315
WO 2002074922	A3	20030220		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,			

09/802376

UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 759590 B2 20030417 AU 2001-23162 20010221
PRIORITY APPLN. INFO.: US 2001-276865P P 20010316
AU 1997-18418 A3 19970128
AB The invention provides methods of maintaining suppression of a Th2 immune response, and methods of maintaining an increase in a Th1 immune response in an individual. The methods generally involve administering to an individual an effective amount of a first dose of a composition comprising an immunomodulatory nucleic acid, and, after a suitable time, administering at least a second dose of a composition comprising an immunomodulatory nucleic acid.
IT 462164-09-6
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleic acid compns. and methods for modulating immune response)
L3 ANSWER 16 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN
ED Entered STN: 05 Jul 2002
ACCESSION NUMBER: 2002:504922 CAPLUS
DOCUMENT NUMBER: 137:73254
TITLE: Immunomodulatory oligonucleotides containing immunostimulatory sequences for treatment of disorders associated with a Th2-type immune response
INVENTOR(S): Fearon, Karen L.; Dina, Dino
PATENT ASSIGNEE(S): Dynavax Technologies Corporation, USA
SOURCE: PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002052002	A2	20020704	WO 2001-US50821	20011227
WO 2002052002	A3	20030904		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003049266	A1	20030313	US 2001-33243	20011227
EP 1364010	A2	20031126	EP 2001-991610	20011227
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			

Searcher : Shears 571-272-2528

09/802376

JP 2004525616 T2 20040826 JP 2002-553483 20011227
PRIORITY APPLN. INFO.: US 2000-258675P P 20001227
WO 2001-US50821 W 20011227

OTHER SOURCE(S): MARPAT 137:73254

AB The invention provides **immunomodulatory** polynucleotides and methods for **immunomodulation** of individuals using the **immunomodulatory** polynucleotides. Each **immunomodulatory** polynucleotide comprises at least one immunostimulatory sequence (ISS). Thus, administration of 5'-tgactgtgaazggttgagatga-3' (where z = 5-bromocytosine) in conjunction with hepatitis B surface antigen (HBsAg) to baboons resulted in increased titers of anti-HBsAg antibodies as compared to administration of HBsAg alone or to administration of HBsAg with a non-ISS oligonucleotide. Complexation of **immunomodulatory** polynucleotides with cationic poly(lactic acid, glycolic acid) microspheres in a human PBMC assay showed significantly enhanced induction of interferon α and interferon γ in comparison to the polynucleotides alone.

IT 440004-73-9 440004-74-0 440004-81-9
440004-82-0

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(**immunomodulatory** oligonucleotides containing immunostimulatory sequences for treatment of disorders associated with a Th2-type immune response)

IT 439896-90-9

RL: PRP (Properties)

(unclaimed sequence; **immunomodulatory** oligonucleotides containing immunostimulatory sequences for treatment of disorders associated with a Th2-type immune response)

L3 ANSWER 17 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN

ED Entered STN: 05 Apr 2002

ACCESSION NUMBER: 2002:256024 CAPLUS

DOCUMENT NUMBER: 136:293507

TITLE: Microparticles for delivery of the heterologous nucleic acids

INVENTOR(S): O'Hagan, Derek; Otten, Gillis; Donnelly, John James; Polo, John M.; Barnett, Susan; Singh, Manmohan; Ulmer, Jeffrey; Dubensky, Thomas W., Jr.

PATENT ASSIGNEE(S): Chiron Corporation, USA

SOURCE: PCT Int. Appl., 100 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002026209	A2	20020404	WO 2001-US30540	20010928
WO 2002026209	A3	20030103		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN,

Searcher : Shears 571-272-2528

YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2001094897 A5 20020408 AU 2001-94897 20010928
 BR 2001014305 A 20030701 BR 2001-14305 20010928
 EP 1322287 A2 20030702 EP 2001-975584 20010928
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 US 2003138453 A1 20030724 US 2001-967464 20010928
 JP 2004518631 T2 20040624 JP 2002-530039 20010928
 PRIORITY APPLN. INFO.: US 2000-236105P P 20000928
 US 2001-315905P P 20010830
 WO 2001-US30540 W 20010928

AB Microparticles with adsorbent surfaces, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(α -hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents. Also provided are microparticles in the form of submicron emulsions of an oil droplet emulsion having a metabolizable oil and an emulsifying agent. The surface of the microparticles efficiently adsorb polypeptides, such as antigens, and nucleic acids, such as ELVIS vectors and other vector constructs, containing heterologous nucleotide sequences encoding biol.

active

macromols., such as polypeptides, antigens, and adjuvants. Methods of stimulating an immune response, methods of immunizing a host animal against a viral, bacterial, or parasitic infection, and uses of the microparticle comps. for vaccines are also provided.

IT 406856-76-6

RL: PRP (Properties)

(unclaimed nucleotide sequence; microparticles for delivery of the heterologous nucleic acids)

L3 ANSWER 18 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN

ED Entered STN: 16 Nov 2001

ACCESSION NUMBER: 2001:833485 CAPLUS

DOCUMENT NUMBER: 135:366775

TITLE: Agents that modulate DNA-PK activity and methods of use thereof

INVENTOR(S): Raz, Eyal; Lois, Augusto F.; Takabayashi, Kenji

PATENT ASSIGNEE(S): The Regents of the University of California, USA

SOURCE: PCT Int. Appl., 57 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001085910	A2	20011115	WO 2001-US14508	20010504
WO 2001085910	A3	20020404		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
 HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,

LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
 RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
 VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2001074817 A5 20011120 AU 2001-74817 20010504
 US 2003176373 A1 20030918 US 2001-848986 20010504
 US 2003125284 A1 20030703 US 2002-233121 20020830
 PRIORITY APPLN. INFO.: US 2000-202274P P 20000505
 US 2001-262321P P 20010117
 US 2001-848986 A3 20010504
 WO 2001-US14508 W 20010504

AB The present invention provides methods for modulating cell death in a eukaryotic cell, and methods for reducing DNA damage in a eukaryotic cell. The methods generally comprise modulating a biol. activity of DNA-PK in a cell. The invention further provides method of treating a condition related to cell death in an individual. The invention further provides methods of identifying agents which modulate a biol. activity of DNA-PK, as well as agents identified by the methods. Methods of **modulating** an **immune** response using an identified agent are also provided.

IT **217447-24-0 220600-99-7**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (agents that modulate DNA-PK activity and methods of use thereof)

L3 ANSWER 19 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN
 ED Entered STN: 17 Oct 2001
 ACCESSION NUMBER: 2001:755469 CAPLUS
 DOCUMENT NUMBER: 136:288732
 TITLE: Immunostimulatory DNA inhibits IL-4-dependent IgE synthesis by human B cells
 AUTHOR(S): Homer, Anthony A.; Widhopf, George F.; Burger, Jan A.; Takabayashi, Kenji; Cinman, Nadya; Ronaghy, Arash; Spiegelberg, Hans L.; Raz, Eyal
 CORPORATE SOURCE: Departments of Medicine, University of California, San Diego, CA, 92093-0663, USA
 SOURCE: Journal of Allergy and Clinical Immunology (2001), 108(3), 417-423
 CODEN: JACIBY; ISSN: 0091-6749
 PUBLISHER: Mosby, Inc.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Immunostimulatory sequence oligodeoxynucleotide (ISS-ODN) is a potent antiallergic **immunomodulating** agent in mice. However, few studies have addressed its antiallergic potential in human subjects. The authors sought to determine whether a phosphorothioate ISS-ODN could inhibit IL-4-dependent IgE synthesis by human B cells. Initially, nonatopic- and atopic-donor PBMCs were incubated with ISS-ODN or mutated oligodeoxynucleotide, and cytokine production and B-cell expression of IFN- γ receptor and IL-4 receptor were measured by using ELISA and flow cytometry, resp. In subsequent studies atopic-donor PBMCs were incubated with IL-4 alone or with ISS-ODN or mutated oligodeoxynucleotide. After 14 days, IgE production and IgM, IgG, and IgA production were determined by using

ELISA. In select IgE studies cytokines were neutralized with mAbs. ISS-ODN induced IL-12, IFN- α , IFN- γ , IL-10, and IL-6 production from both nonatopic- and atopic-donor PBMCs. ISS-ODN also increased IFN- γ receptor and inhibited IL-4 receptor expression on B cells from both donor populations. Furthermore, ISS-ODN inhibited IL-4-dependent IgE production by atopic-donor PBMCs. Neutralization of IL-12, IFN- α , IFN- γ , and IL-10, but not IL-6, attenuated the inhibitory activity of ISS-ODN on IgE production. In contrast to its inhibition of IgE synthesis, ISS-ODN stimulated the production of IgM, IgG, and IgA. Thus, phosphorothioate ISS-ODN elicits an innate immune response by PBMCs, which inhibits IL-4-dependent IgE synthesis. These results provide further support for consideration of ISS-ODN therapy for the treatment of allergic disease in clin. practice.

IT 408555-79-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(immunostimulatory DNA inhibits interleukin-4-dependent IgE biosynthesis by human B cells)

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 20 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN

ED Entered STN: 21 Sep 2001

ACCESSION NUMBER: 2001:693137 CAPLUS

DOCUMENT NUMBER: 135:271874

TITLE: Biodegradable immunomodulatory formulations and methods for use thereof

INVENTOR(S): Van Nest, Gary; Tuck, Stephen

PATENT ASSIGNEE(S): Dynavax Technologies Corporation, USA

SOURCE: PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001068144	A2	20010920	WO 2001-US7848	20010312
WO 2001068144	A3	20020516		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 2003129251	A1	20030710	US 2001-802359	20010309
EP 1261378	A2	20021204	EP 2001-918571	20010312
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2003526682	T2	20030909	JP 2001-566707	20010312
PRIORITY APPLN. INFO.:			US 2000-188303P	P 20000310

09/802376

US 2001-802359

A2 20010309

WO 2001-US7848

W 20010312

AB The invention provides new compns. and methods for **immunomodulation** of individuals. **Immunomodulation** is accomplished by administration of **immunomodulatory** polynucleotide/microcarrier (IMP/MC) complexes. The IMP/MC complexes may be covalently or non-covalently bound, and feature a polynucleotide comprising at least one immunostimulatory sequence bound to a biodegradable microcarrier or nanocarrier.

IT 217447-24-0 217638-05-6 217638-06-7

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(formulations comprising immunostimulatory polynucleotide and biodegradable microcarrier or nanocarrier for)

L3 ANSWER 21 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN

ED Entered STN: 21 Sep 2001

ACCESSION NUMBER: 2001:693136 CAPLUS

DOCUMENT NUMBER: 135:262226

TITLE: **Immunomodulatory** formulations and methods for use thereof

INVENTOR(S): Van Nest, Gary; Tuck, Stephen

PATENT ASSIGNEE(S): Dynavax Technologies Corporation, USA

SOURCE: PCT Int. Appl., 61 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001068143	A2	20010920	WO 2001-US7843	20010312
WO 2001068143	A3	20020516		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 2002055477	A1	20020509	US 2001-802376	20010309
EP 1261377	A2	20021204	EP 2001-918568	20010312
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004502645	T2	20040129	JP 2001-566706	20010312
PRIORITY APPLN. INFO.:			US 2000-188557P	P 20000310
			US 2001-802376	A2 20010309
			WO 2001-US7843	W 20010312

AB The invention provides new compns. and methods for **immunomodulation** of individuals. **Immunomodulation** is accomplished by administration of **immunomodulatory** polynucleotide/microcarrier (IMP/MC) complexes. The IMP/MC complexes may be covalently or non-covalently bound, and feature a polynucleotide

Searcher : Shears 571-272-2528

comprising at least one immunostimulatory sequence bound to a nonbiodegradable microcarrier or nanocarrier.

IT **251974-00-2**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(**immunomodulatory** oligonucleotide formulations and methods for use thereof)

L3 ANSWER 22 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN

ED Entered STN: 21 Sep 2001

ACCESSION NUMBER: 2001:693111 CAPLUS

DOCUMENT NUMBER: 135:267201

TITLE: Methods of reducing papillomavirus infection using **immunomodulatory** polynucleotide sequences

INVENTOR(S): Van Nest, Gary

PATENT ASSIGNEE(S): Dynavax Technologies Corporation, USA

SOURCE: PCT Int. Appl., 44 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001068117	A2	20010920	WO 2001-US7842	20010312
WO 2001068117	A3	20020808		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 2002107212	A1	20020808	US 2001-802445	20010309
EP 1261353	A2	20021204	EP 2001-916582	20010312
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2003526673	T2	20030909	JP 2001-566681	20010312
PRIORITY APPLN. INFO.:			US 2000-188265P	P 20000310
			US 2001-802445	A 20010309
			WO 2001-US7842	W 20010312

AB The invention provides methods for the treatment of papillomavirus infections. A polynucleotide comprising an immunostimulatory sequence is administered to an individual who has been exposed to or infected by papillomavirus. The polynucleotide is not administered with papillomavirus antigen. Administration of the polynucleotide results in amelioration of symptoms of papillomavirus infection.

IT **217447-24-0**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(immunostimulatory polynucleotide sequences for reducing papillomavirus

infection)

L3 ANSWER 23 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN
 ED Entered STN: 21 Sep 2001
 ACCESSION NUMBER: 2001:693110 CAPLUS
 DOCUMENT NUMBER: 135:267200
 TITLE: Methods of preventing and treating respiratory viral
 infection using **immunomodulatory**
 polynucleotide sequences
 INVENTOR(S): Van Nest, Gary
 PATENT ASSIGNEE(S): Dynavax Technologies Corporation, USA
 SOURCE: PCT Int. Appl., 40 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001068116	A2	20010920	WO 2001-US7839	20010312
WO 2001068116	A3	20020808		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 2001046967	A1	20011129	US 2001-802686	20010309
EP 1261352	A2	20021204	EP 2001-916581	20010312
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2003526672	T2	20030909	JP 2001-566680	20010312
PRIORITY APPLN. INFO.:			US 2000-188583P	P 20000310
			US 2001-802686	A2 20010309
			WO 2001-US7839	W 20010312

AB The invention provides methods of preventing and/or treating infection by a respiratory virus such as respiratory syncytial virus (RSV), particularly reducing infection and/or one or more symptoms of respiratory virus infection. A polynucleotide comprising an immunostimulatory sequence (an "ISS") is administered to an individual which is at risk of being exposed to a respiratory virus, has been exposed to a respiratory virus or is infected with a respiratory virus. The ISS is administered without any antigens of the respiratory virus. Administration of the ISS results in reduced incidence and/or severity of one or more symptoms of respiratory virus infection.

IT **217447-24-0**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(immunostimulatory polynucleotide sequences for preventing and treating respiratory viral infection)

L3 ANSWER 24 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN
 ED Entered STN: 21 Sep 2001
 ACCESSION NUMBER: 2001:693098 CAPLUS
 DOCUMENT NUMBER: 135:267199
 TITLE: Methods of ameliorating symptoms of herpes infection
 using **immunomodulatory** polynucleotide
 sequences
 INVENTOR(S): Van Nest, Gary
 PATENT ASSIGNEE(S): Dynavax Technologies Corporation, USA
 SOURCE: PCT Int. Appl., 49 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001068103	A2	20010920	WO 2001-US7841	20010312
WO 2001068103	A3	20020808		
WO 2001068103	C2	20030306		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1265622	A2	20021218	EP 2001-957594	20010312
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2003526670	T2	20030909	JP 2001-566667	20010312
PRIORITY APPLN. INFO.:			US 2000-188556P	P 20000310
			US 2001-802518	A 20010309
			WO 2001-US7841	W 20010312

AB The invention provides new methods of preventing and/or treating herpes virus infections, particularly reducing infection, one or more symptoms and recurrence of one or more symptoms of herpes simplex virus infection. A polynucleotide comprising an immunostimulatory sequence (an "ISS") is administered to an individual which is at risk of being exposed to α -herpesvirinae, has been exposed to α -herpesvirinae or is infected with α -herpesvirinae. The ISS is administered without any α -herpesvirinae antigens. Administration of the ISS results in reduced incidence, recurrence, and severity of one or more symptoms of α -herpesvirinae infection.

IT **217447-24-0**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(methods of ameliorating symptoms of herpes infection using **immunomodulatory** polynucleotide sequences)

L3 ANSWER 25 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN
 ED Entered STN: 21 Sep 2001

09/802376

ACCESSION NUMBER: 2001:693075 CAPLUS
DOCUMENT NUMBER: 135:267227
TITLE: Methods of suppressing hepatitis virus infection using
immunomodulatory polynucleotide sequences
INVENTOR(S): Van Nest, Gary
PATENT ASSIGNEE(S): Dynavax Technologies Corporation, USA
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001068078	A2	20010920	WO 2001-US7931	20010312
WO 2001068078	A3	20020912		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002098199	A1	20020725	US 2001-802370	20010309
EP 1282427	A2	20030212	EP 2001-913361	20010312
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003526662	T2	20030909	JP 2001-566642	20010312
US 2003216340	A1	20031120	US 2003-357760	20030203
PRIORITY APPLN. INFO.:				
			US 2000-188301P	P 20000310
			US 2001-802370	A 20010309
			WO 2001-US7931	W 20010312

AB Methods are provided for the treatment of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. A polynucleotide comprising an immunostimulatory sequence is administered to an individual who has been exposed to or infected by HBV and/or HCV. The polynucleotide is not administered with a HCV or HBV antigen. Administration of the polynucleotide results in amelioration of symptoms of HBV and/or HCV infection.

IT 251974-00-2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(methods of suppressing hepatitis virus infection using **immunomodulatory** polynucleotide sequences in relation to decrease of viral antigen levels)

L3 ANSWER 26 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN

ED Entered STN: 21 Sep 2001

ACCESSION NUMBER: 2001:693074 CAPLUS

DOCUMENT NUMBER: 135:267226

TITLE: Methods of preventing and treating viral infections and using **immunomodulatory** polynucleotide

Searcher : Shears 571-272-2528

INVENTOR(S): sequences
 Van Nest, Gary
 PATENT ASSIGNEE(S): Dynavax Technologies Corporation, USA
 SOURCE: PCT Int. Appl., 65 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001068077	A2	20010920	WO 2001-US7840	20010312
WO 2001068077	A3	20020808		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002028784	A1	20020307	US 2001-802685	20010309
EP 1267893	A2	20030102	EP 2001-918567	20010312
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003535043	T2	20031125	JP 2001-566641	20010312
PRIORITY APPLN. INFO.: US 2000-188302P P 20000310 US 2001-802685 A 20010309 WO 2001-US7840 W 20010312				
AB The invention provides methods of suppression, prevention, and/or treatment of infection by viruses. A polynucleotide comprising an immunostimulatory sequence (an "ISS") is administered to an individual who is at risk of being exposed to, has been exposed to or is infected with a virus. The ISS-containing polynucleotide is administered without any antigens of the virus. Administration of the ISS-containing polynucleotide results in reduced incidence and/or severity of one or more symptoms of virus infection.				
IT 251974-00-2 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (methods of preventing and treating viral infections and using immunomodulatory polynucleotide sequences)				
L3 ANSWER 27 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN ED Entered STN: 31 Aug 2001 ACCESSION NUMBER: 2001:635850 CAPLUS DOCUMENT NUMBER: 135:205543 TITLE: Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation INVENTOR(S): Raz, Eyal; Rachmilewitz, Daniel PATENT ASSIGNEE(S): Regents of the University of California, USA				

09/802376

SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001062207	A2	20010830	WO 2001-US6034	20010222
WO 2001062207	A3	20011220		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 2001041751	A5	20010903	AU 2001-41751	20010222
EP 1259264	A2	20021127	EP 2001-913036	20010222
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRIORITY APPLN. INFO.:			US 2000-184256P	P 20000223
			WO 2001-US6034	W 20010222

AB The invention provides a method for ameliorating gastrointestinal inflammation, particularly chronic gastrointestinal inflammation such as inflammatory bowel disease (IBD), in a subject. In one embodiment, the method comprises administering an **immunomodulatory** nucleic acid to a subject suffering from or susceptible to gastrointestinal inflammation.

IT **251974-00-2**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation using **immunomodulatory** nucleic acids in combination with other agents in relation to biochem. effects)

L3 ANSWER 28 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN

ED Entered STN: 03 Aug 2001

ACCESSION NUMBER: 2001:565220 CAPLUS

DOCUMENT NUMBER: 135:147402

TITLE: **Immunomodulatory** polynucleotides for the treatment of an infection by an intracellular pathogen

INVENTOR(S): Raz, Eyal; Kornbluth, Richard; Catanzaro, Antonio; Hayashi, Tomoko; Carson, Dennis A.

PATENT ASSIGNEE(S): The Regents of the University of California, USA

SOURCE: PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

Searcher : Shears 571-272-2528

09/802376

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001055341	A2	20010802	WO 2001-US3029	20010130
WO 2001055341	A3	20020328		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001031245	A5	20010807	AU 2001-31245	20010130
US 2002086295	A1	20020704	US 2001-774403	20010130
US 6552006	B2	20030422		
EP 1253947	A2	20021106	EP 2001-903430	20010130
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003212028	A1	20031113	US 2003-353917	20030128
PRIORITY APPLN. INFO.:				
			US 2000-179353P	P 20000131
			US 2001-774403	A1 20010130
			WO 2001-US3029	W 20010130
AB	The invention features methods for treatment or prevention of infection by intracellular pathogens (e.g. Mycobacterium species) by administration of an immunomodulatory nucleic acid mol. In one embodiment, an immunomodulatory nucleic acid mol. is administered in combination with another anti-pathogenic agent to provide a synergistic antipathogenic effect.			
IT	220600-99-7 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (immunomodulatory polynucleotides for treatment of infection by intracellular pathogen)			
L3	ANSWER 29 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN			
ED	Entered STN: 29 Jun 2001			
ACCESSION NUMBER:	2001:472530 CAPLUS			
DOCUMENT NUMBER:	135:91513			
TITLE:	Method for preventing an anaphylactic reaction			
INVENTOR(S):	Raz, Eyal; Horner, Anthony A.			
PATENT ASSIGNEE(S):	Regents of the University of California, USA			
SOURCE:	PCT Int. Appl., 38 pp.			
	CODEN: PIXXD2			
DOCUMENT TYPE:	Patent			
LANGUAGE:	English			
FAMILY ACC. NUM. COUNT:	1			
PATENT INFORMATION:				

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001045750	A1	20010628	WO 2000-US35064	20001220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,				

Searcher : Shears 571-272-2528

09/802376

LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-171830P P 19991221

AB The invention provides a method for reducing anaphylactic hypersensitivity response to an allergen in a subject. In one embodiment, the method comprises administering an **immunomodulatory** nucleic acid mol. to the subject. In another embodiment, the method comprises administering antigen with the **immunomodulatory** nucleic acid mol. to the subject, which antigen may be administered as a conjugate with or in admixt. with the **immunomodulatory** nucleic acid mol.

IT 220600-99-7

RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(allergen and immunostimulatory nucleic acid for preventing an anaphylactic reaction)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 30 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN

ED Entered STN: 27 May 2001

ACCESSION NUMBER: 2001:380427 CAPLUS

DOCUMENT NUMBER: 135:496

TITLE: **Immunomodulatory** compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof

INVENTOR(S): Tuck, Stephen; Van Nest, Gary

PATENT ASSIGNEE(S): Dynavax Technologies Corporation, USA

SOURCE: PCT Int. Appl., 97 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001035991	A2	20010525	WO 2000-US31385	20001115
WO 2001035991	A3	20011122		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1229933	A2	20020814	EP 2000-978688	20001115
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2003513680	T2	20030415	JP 2001-537981	20001115
PRIORITY APPLN. INFO.:			US 1999-165467P	P 19991115

Searcher : Shears 571-272-2528

US 2000-713136 A2 20001114
 WO 2000-US31385 W 20001115

AB The invention provides classes of **immunomodulatory** compns. which comprise an average of one or more immunostimulatory sequence (ISS) containing

polynucleotide conjugated, or attached, to antigen. The extent of conjugation affects **immunomodulatory** properties, such as extent of antigen-specific antibody formation, including Th1-associated antibody formation, and thus these various conjugate classes are useful for modulating the type and extent of immune response. The invention also includes methods of **modulating** an **immune** response using these compns.

IT **217638-05-6D**, allergen conjugates **217638-06-7D**, allergen conjugates **251974-00-2D**, allergen conjugates

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(**immunomodulatory** compns. containing an immunostimulatory sequence linked to antigen and methods of use thereof)

L3 ANSWER 31 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN

ED Entered STN: 11 May 2001

ACCESSION NUMBER: 2001:338716 CAPLUS

DOCUMENT NUMBER: 134:349012

TITLE: CpG receptor (CpG-R) and methods relating thereto

INVENTOR(S): MacKichan, Mary Lee

PATENT ASSIGNEE(S): Chiron Corporation, USA

SOURCE: PCT Int. Appl., 41 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032877	A2	20010510	WO 2000-US41735	20001101
WO 2001032877	A3	20020103		
WO 2001032877	C2	20020815		
W: CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
EP 1226251	A2	20020731	EP 2000-989738	20001101
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
JP 2003514219	T2	20030415	JP 2001-535559	20001101
PRIORITY APPLN. INFO.:			US 1999-163157P	P 19991102
			US 1999-167389P	P 19991124
			WO 2000-US41735	W 20001101

AB The present invention is directed to nucleic acid mols. and polypeptides encoding a CpG receptor (CpG-R). The CpG-R contains a toll homol. domain (THD), interacts with the MyD88 adapter protein, and may bind to CpG oligonucleotides. The present invention is also directed to antibodies against CpG-R and to methods of **modulating** an **immune** response and to methods of identifying compds. which bind to and/or modulate CpG-R.

IT 251974-00-2

RL: PRP (Properties)

(unclaimed nucleotide sequence; cpG receptor (CpG-R) and methods relating thereto)

L3 ANSWER 32 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN

ED Entered STN: 25 Feb 2001

ACCESSION NUMBER: 2001:137053 CAPLUS

DOCUMENT NUMBER: 134:192226

TITLE: Methods of **modulating** an **immune** response using immunostimulatory sequences and compositions for use therein

INVENTOR(S): Van Nest, Gary

PATENT ASSIGNEE(S): Dynavax Technologies Corporation, USA

SOURCE: PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001012223	A2	20010222	WO 2000-US22835	20000818
WO 2001012223	A3	20010920		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1204425	A2	20020515	EP 2000-955749	20000818
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
JP 2003507341	T2	20030225	JP 2001-516568	20000818
AU 774380	B2	20040624	AU 2000-67899	20000818
PRIORITY APPLN. INFO.:			US 1999-149768P	P 19990819
			WO 2000-US22835	W 20000818

AB The invention provides methods of **modulating** an **immune** response to a second antigen which entail administration of a first antigen and an immunostimulatory polynucleotide. **Modulation** of the **immune** response is generally manifested as stimulation of a Th1 response.

IT 251974-00-2

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(vaccines comprising a second antigen and immunostimulatory polynucleotide for inducing Th1 response to a first antigen)

L3 ANSWER 33 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN

ED Entered STN: 01 Sep 2000

ACCESSION NUMBER: 2000:608550 CAPLUS

DOCUMENT NUMBER: 133:213150

AB Microparticles with adsorbent surfaces, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(α -hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents. The surface of the microparticles efficiently adsorb biol. active macromols., such as DNA, polypeptides, antigens, and adjuvants. Also provided are compns. of an oil droplet emulsion having a metabolizable oil and an emulsifying agent. Immunogenic compns. having an immunostimulating amount of an antigenic substance, and an immunostimulating amount of an adjuvant composition are also provided. Methods of stimulating an immune response, methods of immunizing a host animal against a viral, bacterial, or parasitic infection, and methods of increasing a Th1 immune response in a host animal by administering to the animal an immunogenic composition of the microparticles, and/or microemulsions of the invention, are also provided.

IT 251974-00-2

RL: PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(microemulsions with adsorbed macromols. and microparticles for stimulation of immunity)

09/802376

L3 ANSWER 34 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN

ED Entered STN: 21 Apr 2000

ACCESSION NUMBER: 2000:260051 CAPLUS

DOCUMENT NUMBER: 132:307238

TITLE: Anti-HIV compositions comprising immunostimulatory polynucleotides and HIV antigens

INVENTOR(S): Tighe, Helen; Raz, Eyal; Schwartz, David; Takabayashi, Kenji

PATENT ASSIGNEE(S): Dynavax Technologies Corporation, USA

SOURCE: PCT Int. Appl., 65 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000021556	A1	20000420	WO 1999-US23677	19991008
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2344558	AA	20000420	CA 1999-2344558	19991008
AU 9964259	A1	20000501	AU 1999-64259	19991008
EP 1117433	A1	20010725	EP 1999-951925	19991008
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			

PRIORITY APPLN. INFO.:
US 1998-103733P P 19981009
US 1999-415186 A 19991007
WO 1999-US23677 W 19991008

AB The invention relates to anti-viral **immunomodulatory** compns. comprising immunostimulatory polynucleotides and HIV antigens, such as gpl20. Methods for **modulating** an **immune** response upon administration of the oligonucleotide and antigen compns. are also disclosed.

IT **217447-24-0**

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(anti-HIV compns. comprising immunostimulatory polynucleotides and HIV antigens)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 35 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN

ED Entered STN: 10 Dec 1999

ACCESSION NUMBER: 1999:784115 CAPLUS

DOCUMENT NUMBER: 132:18784

TITLE: Immunostimulatory oligonucleotides with modified cytosine, and methods of use thereof

INVENTOR(S): Schwartz, David

Searcher : Shears 571-272-2528

09/802376

PATENT ASSIGNEE(S): Dynavax Technologies Corporation, USA
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9962923	A2	19991209	WO 1999-US12538	19990604
WO 9962923	A3	20010531		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6562798	B1	20030513	US 1999-324191	19990601
CA 2330225	AA	19991209	CA 1999-2330225	19990604
EP 1121373	A2	20010808	EP 1999-927241	19990604
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
AU 760304	B2	20030515	AU 1999-44194	19990604
AU 9944194	A1	19991220		
US 2004092468	A1	20040513	US 2003-365678	20030210
PRIORITY APPLN. INFO.:			US 1998-88310P	P 19980605
			US 1999-324191	A 19990601
			WO 1999-US12538	W 19990604

AB **Immunomodulatory** oligonucleotide compns. are disclosed. These oligonucleotides comprise an immunostimulatory hexanucleotide sequence including a modified cytosine. These oligonucleotides can be administered in conjunction with an **immunomodulatory** peptide or antigen. Methods of **modulating** an **immune** response upon administration of the oligonucleotide comprising a modified immunostimulatory sequence are also disclosed.

IT **217638-05-6 217638-06-7 251974-00-2**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(immunostimulatory oligonucleotides with modified cytosine, and methods of use)

L3 ANSWER 36 OF 36 CAPLUS COPYRIGHT 2004 ACS on STN

ED Entered STN: 31 Dec 1998

ACCESSION NUMBER: 1998:813720 CAPLUS

DOCUMENT NUMBER: 130:65226

TITLE: Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof

INVENTOR(S): Schwartz, David; Roman, Mark; Dina, Dino

PATENT ASSIGNEE(S): Dynavax Technologies Corp., USA

SOURCE: PCT Int. Appl., 63 pp.

CODEN: PIXXD2

Searcher : Shears 571-272-2528

09/802376

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9855495	A2	19981210	WO 1998-US11578	19980605
WO 9855495	A3	19990527		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9878178	A1	19981221	AU 1998-78178	19980605
AU 753172	B2	20021010		
EP 986572	A2	20000322	EP 1998-926311	19980605
EP 986572	B1	20031022		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6225292	B1	20010501	US 1998-92314	19980605
JP 2002517156	T2	20020611	JP 1999-502884	19980605
AT 252596	E	20031115	AT 1998-926311	19980605
EP 1374894	A2	20040102	EP 2003-20257	19980605
EP 1374894	A3	20040922		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
HK 1024701	A1	20040130	HK 2000-102617	20000429
US 2002086839	A1	20020704	US 2001-770943	20010125
PRIORITY APPLN. INFO.:			US 1997-48793P	P 19970606
			EP 1998-926311	A3 19980605
			US 1998-92314	A1 19980605
			WO 1998-US11578	W 19980605
AB	The invention relates to immunostimulatory oligonucleotide compns. These oligonucleotides comprise an immunostimulatory octanucleotide sequence. These oligonucleotides can be administered in conjunction with an immunostimulatory peptide or antigen. Methods for modulating an immune response upon administration of the oligonucleotide are also disclosed. In addition, an in vitro screening method to identify oligonucleotides with immunostimulatory activity is provided. Compns. containing the immunostimulatory oligonucleotide, antigen, adjuvant and co-stimulatory mol. (e.g. cytokine) are useful for treating cancer, allergy, asthma, viral infection, bacterial infection, and parasitic infection.			
IT	217447-24-0 217638-05-6 217638-06-7 RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (compns. containing immunostimulatory oligonucleotides, antigen, adjuvant, and costimulatory mol. for treating cancer, asthma, and infections)			
E1 THROUGH E42 ASSIGNED				

Searcher : Shears 571-272-2528

09/802376

FILE 'REGISTRY' ENTERED AT 12:00:36 ON 01 NOV 2004

L4 42 SEA FILE=REGISTRY ABB=ON PLU=ON (251974-00-2/BI OR 217447-24-0/BI OR 217638-05-6/BI OR 217638-06-7/BI OR 220600-99-7/BI OR 503638-07-1/BI OR 406856-76-6/BI OR 408555-79-3/BI OR 439896-90-9/BI OR 440004-73-9/BI OR 440004-74-0/BI OR 440004-81-9/BI OR 440004-82-0/BI OR 462164-09-6/BI OR 479469-88-0/BI OR 482386-35-6/BI OR 482387-18-8/BI OR 482661-42-7/BI OR 482663-60-5/BI OR 483382-52-1/BI OR 483382-54-3/BI OR 491894-86-1/BI OR 492479-51-3/BI OR 499810-15-0/BI OR 515181-95-0/BI OR 552901-87-8/BI OR 552901-88-9/BI OR 554461-70-0/BI OR 556163-51-0/BI OR 628357-70-0/BI OR 630432-24-5/BI OR 631925-82-1/BI OR 631926-19-7/BI OR 632370-48-0/BI OR 645428-19-9/BI OR 646074-82-0/BI OR 647920-72-7/BI OR 661771-84-2/BI OR 711385-52-3/BI OR 718384-16-8/BI OR 718384-37-3/BI OR 721175-12-8/BI)

L5 42 L1 AND L4

L5 ANSWER 1 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN
RN 721175-12-8 REGISTRY
CN INDEX NAME NOT YET ASSIGNED
CI MAN
SQL 22

SEQ 1 tgactgtgaa cgttcgagat ga
=====

HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 141:99693

L5 ANSWER 2 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN
RN 718384-37-3 REGISTRY
CN DNA, d(T-G-A-C-T-G-T-G-A-A-C-G-T-T-C-G-A-G-A-T-G-A) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 7: PN: US20040132677 SEQID: 2 unclaimed DNA
CI MAN
SQL 22

SEQ 1 tgactgtgaa cgttcgagat ga
=====

HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 141:99687

L5 ANSWER 3 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN
RN 718384-16-8 REGISTRY
CN 160: PN: US20040132677 SEQID: 139 unclaimed DNA (9CI) (CA INDEX NAME)
CI MAN
SQL 66

SEQ 1 tgactgtgaa cgttcgagat gatgactgtg aacgttcgag atgatgactg
=====

51 tgaacgttcg agatga

Searcher : Shears 571-272-2528

09/802376

=====

HITS AT: 1-66

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 141:99687

L5 ANSWER 4 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN
RN 711385-52-3 REGISTRY
CN DNA, d(T-G-A-C-T-G-T-G-A-A-C-G-T-T-C-G-A-G-A-T-G-A) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 12: PN: WO2004052293 SEQID: 12 claimed DNA
CI MAN
SQL 22

SEQ 1 tgactgtgaa cgttcgagat ga
=====

HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 141:70229

L5 ANSWER 5 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN
RN 661771-84-2 REGISTRY
CN DNA, d(T-G-A-C-T-G-T-G-A-A-C-G-T-T-C-G-A-G-A-T-G-A) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 219: PN: WO2004014322 SEQID: 1 unclaimed DNA
CI MAN
SQL 22

SEQ 1 tgactgtgaa cgttcgagat ga
=====

HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 140:198064

L5 ANSWER 6 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN
RN 647920-72-7 REGISTRY
CN DNA, d(T-G-A-C-T-G-T-G-A-A-C-G-T-T-C-G-A-G-A-T-G-A) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 39: PN: WO2004006848 PAGE: 43 unclaimed DNA
CI MAN
SQL 22

SEQ 1 tgactgtgaa cgttcgagat ga
=====

HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 140:139452

L5 ANSWER 7 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN

Searcher : Shears 571-272-2528

09/802376

RN 646074-82-0 REGISTRY
CN DNA, d(P-thio) (T-G-A-C-T-G-T-G-A-A-C-G-T-T-C-G-A-G-A-T-G-A) (9CI) (CA INDEX NAME)
CI MAN
SQL 22

SEQ 1 tgactgtgaa cgttcgagat ga
===== ==

HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 140:105233

L5 ANSWER 8 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN
RN 645428-19-9 REGISTRY
CN DNA, d(T-G-A-C-T-G-T-G-A-A-C-G-T-T-C-G-A-G-A-T-G-A) (9CI) (CA INDEX NAME)
CI MAN
SQL 22

SEQ 1 tgactgtgaa cgttcgagat ga
===== ==

HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 140:105233

L5 ANSWER 9 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN
RN 632370-48-0 REGISTRY
CN DNA, d(T-G-A-C-T-G-T-G-A-A-C-G-T-T-C-G-A-G-A-T-G-A), 5',5'',5'''-[O,O',O''-[nitrilotris[2,1-ethanediyl(2,5-dioxo-1,3-pyrrolidinediyl)thio-3,1-propanediyl]] tris(hydrogen phosphorothioate)] (9CI) (CA INDEX NAME)
CI MAN
SQL 66,44,22

SEQ 1 agtagagctt gcaagtgtca gttgactgtg aacgttcgag atga
===== ==

HITS AT: 23-44

SEQ 1 tgactgtgaa cgttcgagat ga
===== ==

HITS AT: 1-22

REFERENCE 1: 140:26897

L5 ANSWER 10 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN
RN 631926-19-7 REGISTRY
CN DNA, d(T-G-A-C-T-G-T-G-A-A-C-G-T-T-C-G-A-G-A-T-G-A), 5'-[O-[6-[(6-hydroxyhexyl)dithio]hexyl] hydrogen phosphorothioate] (9CI) (CA INDEX NAME)
CI MAN
SQL 22

SEQ 1 tgactgtgaa cgttcgagat ga
===== ==

Searcher : Shears 571-272-2528

HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 140:26897

L5 ANSWER 11 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN

RN **631925-82-1** REGISTRY

CN DNA, d(T-sp-G-sp-A-sp-C-sp-T-sp-G-sp-T-sp-G-sp-A[oxy(mercaptophosphinylidene)oxy-1,2-ethanediylloxy-1,2-ethanediylloxy-1,2-ethanediylloxy-1,2-ethanediylloxy-1,2-ethanediylloxy(mercaptophosphinylidene)oxy]A-sp-C-sp-G-sp-T-sp-T-sp-C-sp-G[oxy(mercaptophosphinylidene)oxy-1,2-ethanediylloxy-1,2-ethanediylloxy-1,2-ethanediylloxy-1,2-ethanediylloxy(mercaptophosphinylidene)oxy]A-sp-G-sp-A-sp-T-sp-G-sp-A-sp-T)(9CI) (CA INDEX NAME)

CI MAN

SQL 23

SEQ 1 tgactgtgaa cgttcgagat gat
=====

HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 140:26897

L5 ANSWER 12 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN

RN **630432-24-5** REGISTRY

CN DNA, d(T-G-A-C-T-G-T-G-A-A-C-G-T-T-C-G-A-G-A-T-G-A) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 51: PN: US20030225016 SEQID: 2 unclaimed DNA

CI MAN

SQL 22

SEQ 1 tgactgtgaa cgttcgagat ga
=====

HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 140:26897

L5 ANSWER 13 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN

RN **628357-70-0** REGISTRY

CN DNA, d(P-thio) (T-G-A-C-T-G-T-G-A-A-C-G-T-T-C-G-A-G-A-T-G-A) (9CI) (CA INDEX NAME)

CI MAN

SQL 22

SEQ 1 tgactgtgaa cgttcgagat ga
=====

HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

09/802376

REFERENCE 1: 140:26897

L5 ANSWER 14 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN
RN 556163-51-0 REGISTRY
CN DNA, d(T-G-A-C-T-G-T-G-A-A-C-G-T-T-C-G-A-G-A-T-G-A) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1: PN: US20030130217 SEQID: 1 unclaimed DNA
CI MAN
SQL 22

SEQ 1 tgactgtgaa cgttcgagat ga
=====

HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 139:79154

L5 ANSWER 15 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN
RN 554461-70-0 REGISTRY
CN DNA, d(T-G-A-C-T-G-T-G-A-A-C-G-T-T-C-G-A-G-A-T-G-A) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2: PN: US6589940 SEQID: 2 claimed DNA
CI MAN
SQL 22

SEQ 1 tgactgtgaa cgttcgagat ga
=====

HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 139:83965

L5 ANSWER 16 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN
RN 552901-88-9 REGISTRY
CN DNA, d(T-G-A-C-T-G-T-G-A-A-br5C-G-T-T-br5C-G-A-G-A-T-G-A) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 26: PN: US6589940 SEQID: 16 claimed DNA
CI MAN
SQL 22

SEQ 1 tgactgtgaa cgttcgagat ga
=====

HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 139:83965

L5 ANSWER 17 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN
RN 552901-87-8 REGISTRY
CN DNA, d(T-G-A-C-T-G-T-G-A-A-br5C-G-T-T-C-G-A-G-A-T-G-A) (9CI) (CA INDEX NAME)
OTHER NAMES:

Searcher : Shears 571-272-2528

09/802376

CN 25: PN: US6589940 SEQID: 15 claimed DNA
CI MAN
SQL 22

SEQ 1 tgactgtgaa cgttcgagat ga
===== ==
HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 139:83965

L5 ANSWER 18 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN
RN 515181-95-0 REGISTRY
CN DNA, d(P-thio) (T-G-A-C-T-G-T-G-A-A-C-G-T-T-C-G-A-G-A-T-G-A) (9CI) (CA
INDEX NAME)
OTHER NAMES:
CN 1: PN: US20030078223 SEQID: 1 claimed DNA
CI MAN
SQL 22

SEQ 1 tgactgtgaa cgttcgagat ga
===== ==
HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 138:331689

L5 ANSWER 19 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN
RN 503638-07-1 REGISTRY
CN DNA, d(T-G-A-C-T-G-T-G-A-A-C-G-T-T-C-G-A-G-A-T-G-A) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1: PN: US20030059773 SEQID: 1 claimed DNA
CI MAN
SQL 22

SEQ 1 tgactgtgaa cgttcgagat ga
===== ==
HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 141:99687

REFERENCE 2: 138:292710

L5 ANSWER 20 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN
RN 499810-15-0 REGISTRY
CN DNA, d(T-G-A-C-T-G-T-G-A-A-C-G-T-T-C-G-A-G-A-T-G-A) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 44: PN: WO03014316 SEQID: 2 unclaimed DNA
CI MAN
SQL 22

SEQ 1 tgactgtgaa cgttcgagat ga

Searcher : Shears 571-272-2528

09/802376

===== ==
HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 138:210275

L5 ANSWER 21 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN
RN **492479-51-3** REGISTRY
CN DNA, d(P-thio) (T-G-A-C-T-G-T-G-A-A-C-G-T-T-C-G-A-G-A-T-G-A) (9CI) (CA INDEX NAME)
CI MAN
SQL 22

SEQ 1 tgactgtgaa cgttcgagat ga
===== ==
HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 138:142468

L5 ANSWER 22 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN
RN **491894-86-1** REGISTRY
CN DNA, d(T-G-A-C-T-G-T-G-A-A-C-G-T-T-C-G-A-G-A-T-G-A) (9CI) (CA INDEX NAME)
CI MAN
SQL 22

SEQ 1 tgactgtgaa cgttcgagat ga
===== ==
HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 138:142468

L5 ANSWER 23 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN
RN **483382-54-3** REGISTRY
CN DNA, d(P-thio) (T-G-A-C-T-G-T-G-A-A-C-G-T-T-C-G-A-G-A-T-G-A),
5'-[O-(6-mercaptohexyl) hydrogen phosphorothioate] (9CI) (CA INDEX NAME)
CI MAN
SQL 22

SEQ 1 tgactgtgaa cgttcgagat ga
===== ==
HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 138:88635

L5 ANSWER 24 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN
RN **483382-52-1** REGISTRY
CN DNA, d(T-sp-G-sp-A-sp-C-sp-T-sp-G-sp-T-sp-G-sp-A[oxy(mercaptophosphinyldene)oxy-1,3-propanediyl]oxy(mercaptophosphinyldene)oxy]A-sp-C-sp-G-sp-T-sp-T-sp-C-sp-G[oxy(mercaptophosphinyldene)oxy-1,3-

Searcher : Shears 571-272-2528

09/802376

propanediyl oxy(mercaptophosphinylidene) oxy]A-sp-G-sp-A-sp-T-sp-G-sp-A-sp-T)
(9CI) (CA INDEX NAME)
CI MAN
SQL 23

SEQ 1 tgactgtgaa cggttcgagat gat
=====

HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 138:88635

L5 ANSWER 25 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN
RN 482663-60-5 REGISTRY
CN DNA, d(T-sp-G-sp-A-sp-C-sp-T-sp-G-sp-T-sp-G-sp-A[oxym
(mercaptophosphinylidene)oxy-1,2-ethanediyl oxy-1,2-ethanediyl oxy-1,2-ethanediyl oxy-1,2-ethanediyl oxy(mercaptophosphinylidene)oxy]A-sp-C-sp-G-sp-T-sp-T-sp-C-sp-G[oxym
(mercaptophosphinylidene)oxy-1,2-ethanediyl oxy-1,2-ethanediyl oxy-1,2-ethanediyl oxy-1,2-ethanediyl oxy(mercaptophosphinylidene)oxy]A-sp-G-sp-A-sp-T-sp-G-sp-A-sp-T)
(9CI) (CA INDEX NAME)
CI MAN
SQL 23

SEQ 1 tgactgtgaa cggttcgagat gat
=====

HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 138:88635

L5 ANSWER 26 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN
RN 482661-42-7 REGISTRY
CN DNA, d(T-G-A-C-T-G-T-G-A-A-C-G-T-T-C-G-A-G-A-T-G-A), 5',5'',5''''-[O,O',O''-[nitrilotris[2,1-ethanediyl(2,5-dioxo-1,3-pyrrolidinediyl)thio-3,1-propanediyl]] tris(hydrogen phosphorothioate)] (9CI) (CA INDEX NAME)
CI MAN
SQL 66,22,22,22

SEQ 1 tgactgtgaa cggttcgagat ga
=====

HITS AT: 1-22

SEQ 1 tgactgtgaa cggttcgagat ga
=====

HITS AT: 1-22

SEQ 1 tgactgtgaa cggttcgagat ga
=====

HITS AT: 1-22

REFERENCE 1: 138:88635

09/802376

L5 ANSWER 27 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN
RN **482387-18-8** REGISTRY
CN 129: PN: WO03000922 SEQID: 139 unclaimed DNA (9CI) (CA INDEX NAME)
CI MAN
SQL 66

SEQ 1 tgactgtgaa cgttcgagat gatgactgtg aacgttcgag atgatgactg
=====
51 tgaacgttcg agatga
=====

HITS AT: 1-66

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 138:88635

L5 ANSWER 28 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN
RN **482386-35-6** REGISTRY
CN DNA, d(T-G-A-C-T-G-T-G-A-A-C-G-T-T-C-G-A-G-A-T-G-A) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2: PN: WO03000922 SEQID: 2 unclaimed DNA
CI MAN
SQL 22

SEQ 1 tgactgtgaa cgttcgagat ga
=====

HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 138:88635

L5 ANSWER 29 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN
RN **479469-88-0** REGISTRY
CN DNA, d(P-thio) (T-G-A-C-T-G-T-G-A-A-C-G-T-T-C-G-A-G-A-T-G-A) (9CI) (CA INDEX NAME)
CI MAN
SQL 22

SEQ 1 tgactgtgaa cgttcgagat ga
=====

HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 138:88635

L5 ANSWER 30 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN
RN **462164-09-6** REGISTRY
CN DNA, d(P-thio) (T-G-A-C-T-G-T-G-A-A-C-G-T-T-C-G-A-G-A-T-G-A) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2: PN: WO02074922 SEQID: 2 claimed DNA
CI MAN
SQL 22

09/802376

SEQ 1 tgactgtgaa cgttcgagat ga
=====

HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 137:273193

L5 ANSWER 31 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN

RN 440004-82-0 REGISTRY

CN DNA, d(T-G-A-C-T-G-T-G-A-A-C-s6G-T-T-C-s6G-A-G-A-T-G-A) (9CI) (CA INDEX
NAME)

OTHER NAMES:

CN 48: PN: WO02052002 SEQID: 48 claimed sequence

CI MAN

SQL 22

SEQ 1 tgactgtgaa cgttcgagat ga
=====

HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 137:73254

L5 ANSWER 32 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN

RN 440004-81-9 REGISTRY

CN DNA, d(T-G-A-C-T-G-T-G-A-A-C-G-s4T-T-C-G-A-G-A-T-G-A) (9CI) (CA INDEX
NAME)

OTHER NAMES:

CN 47: PN: WO02052002 SEQID: 47 claimed sequence

CI MAN

SQL 22

SEQ 1 tgactgtgaa cgttcgagat ga
=====

HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 137:73254

L5 ANSWER 33 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN

RN 440004-74-0 REGISTRY

CN DNA, d(T-G-A-C-T-G-T-G-A-A-br5C-G-T-T-br5C-G-A-G-A-T-G-A) (9CI) (CA INDEX
NAME)

OTHER NAMES:

CN 38: PN: WO02052002 SEQID: 38 claimed sequence

CI MAN

SQL 22

SEQ 1 tgactgtgaa cgttcgagat ga
=====

HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Searcher : Shears 571-272-2528

09/802376

REFERENCE 1: 137:73254

L5 ANSWER 34 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN
RN 440004-73-9 REGISTRY
CN DNA, d(T-G-A-C-T-G-T-G-A-A-br5C-G-T-T-C-G-A-G-A-T-G-A) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 37: PN: WO02052002 SEQID: 37 claimed DNA
CI MAN
SQL 22

SEQ 1 tgactgtgaa cgttcgagat ga
=====

HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 137:73254

L5 ANSWER 35 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN
RN 439896-90-9 REGISTRY
CN DNA, d(T-G-A-C-T-G-T-G-A-A-C-G-T-T-C-G-A-G-A-T-G-A) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 59: PN: WO02052002 SEQID: 59 unclaimed DNA
CI MAN
SQL 22

SEQ 1 tgactgtgaa cgttcgagat ga
=====

HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 137:73254

L5 ANSWER 36 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN
RN 408555-79-3 REGISTRY
CN DNA, d(P-thio)(T-G-A-C-T-G-T-G-A-A-C-G-T-T-C-G-A-G-A-T-G-A) (9CI) (CA INDEX NAME)
CI MAN
SQL 22

SEQ 1 tgactgtgaa cgttcgagat ga
=====

HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 136:288732

L5 ANSWER 37 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN
RN 406856-76-6 REGISTRY
CN 19: PN: WO0226209 SEQID: 19 unclaimed DNA (9CI) (CA INDEX NAME)
CI MAN
SQL 22

Searcher : Shears 571-272-2528

09/802376

SEQ 1 tgactgtgaa cgttcgagat ga
=====

HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 136:293507

L5 ANSWER 38 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN

RN **251974-00-2** REGISTRY

CN DNA, d(T-G-A-C-T-G-T-G-A-A-C-G-T-T-C-G-A-G-A-T-G-A) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 12: PN: WO0050006 SEQID: 19 claimed DNA

CN 12: PN: WO0050075 PAGE: 9 claimed DNA

CN 1: PN: WO0062787 PAGE: 18 claimed DNA

CN 1: PN: WO0135991 SEQID: 1 claimed DNA

CN 1: PN: WO0143778 PAGE: 18 unclaimed DNA

CN 1: PN: WO0168077 SEQID: 1 claimed DNA

CN 1: PN: WO0168143 SEQID: 1 claimed DNA

CN 2: PN: WO0056342 SEQID: 2 claimed DNA

CN 50: PN: WO0132699 SEQID: 21 unclaimed DNA

CI MAN

SQL 22

SEQ 1 tgactgtgaa cgttcgagat ga
=====

HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 135:267227

REFERENCE 2: 135:267226

REFERENCE 3: 135:262226

REFERENCE 4: 135:205543

REFERENCE 5: 135:66218

REFERENCE 6: 135:496

REFERENCE 7: 134:349012

REFERENCE 8: 134:192226

REFERENCE 9: 134:99570

REFERENCE 10: 133:334037

L5 ANSWER 39 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN

RN **220600-99-7** REGISTRY

CN DNA, d(P-thio) (T-G-A-C-T-G-T-G-A-A-C-G-T-T-C-G-A-G-A-T-G-A) (9CI) (CA INDEX NAME)

OTHER NAMES:

Searcher : Shears 571-272-2528

09/802376

CN 1: PN: WO0145750 SEQID: 1 claimed DNA
CN 1: PN: WO0155341 SEQID: 1 claimed DNA
CI MAN
SQL 22

SEQ 1 tgactgtgaa cgttcgagat ga
===== ==
HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 135:366775
REFERENCE 2: 135:287151
REFERENCE 3: 135:147402
REFERENCE 4: 135:91513
REFERENCE 5: 134:146304
REFERENCE 6: 133:3455
REFERENCE 7: 131:270631
REFERENCE 8: 130:232485
REFERENCE 9: 130:181397

L5 ANSWER 40 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN
RN 217638-06-7 REGISTRY
CN DNA, d(T-G-A-C-T-G-T-G-A-A-br5C-G-T-T-br5C-G-A-G-A-T-G-A) (9CI) (CA INDEX
NAME)
OTHER NAMES:
CN 8: PN: WO0135991 SEQID: 8 claimed DNA
CI MAN
SQL 22

SEQ 1 tgactgtgaa cgttcgagat ga
===== ==
HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 135:271874
REFERENCE 2: 135:496
REFERENCE 3: 132:18784
REFERENCE 4: 130:65226

L5 ANSWER 41 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN
RN 217638-05-6 REGISTRY
CN DNA, d(T-G-A-C-T-G-T-G-A-A-br5C-G-T-T-C-G-A-G-A-T-G-A) (9CI) (CA INDEX
NAME)

Searcher : Shears 571-272-2528

OTHER NAMES:

CN 7: PN: WO0135991 SEQID: 7 claimed DNA
 CI MAN
 SQL 22

SEQ 1 tgactgtgaa cgttcgagat ga
 =====

HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 135:271874

REFERENCE 2: 135:496

REFERENCE 3: 132:18784

REFERENCE 4: 130:65226

L5 ANSWER 42 OF 42 REGISTRY COPYRIGHT 2004 ACS on STN

RN 217447-24-0 REGISTRY

CN DNA, d(T-C-A-T-C-T-C-G-A-A-C-G-T-T-C-A-C-A-G-T-C-A), double-stranded
 complementary (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN DNA, d(T-G-A-C-T-G-T-G-A-A-C-G-T-T-C-G-A-G-A-T-G-A), double-stranded
 complementary (9CI)

OTHER NAMES:

CN 19: PN: WO0020039 SEQID: 19 claimed DNA

CN 1: PN: WO0016804 PAGE: 23 unclaimed DNA

CN 1: PN: WO0168103 SEQID: 1 claimed DNA

CN 1: PN: WO0176642 SEQID: 1 unclaimed DNA

CN 2: PN: WO0067787 PAGE: 26 claimed DNA

CN 4: PN: WO0168144 PAGE: 49 claimed DNA

CI MAN

SQL 22

SEQ 1 tgactgtgaa cgttcgagat ga
 =====

HITS AT: 1-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 135:366775

REFERENCE 2: 135:317456

REFERENCE 3: 135:271874

REFERENCE 4: 135:267231

REFERENCE 5: 135:267201

REFERENCE 6: 135:267200

REFERENCE 7: 135:267199

09/802376

REFERENCE 8: 134:4037

REFERENCE 9: 132:307238

REFERENCE 10: 132:278177

(FILE 'MEDLINE, BIOSIS, EMBASE' ENTERED AT 12:02:11 ON 01 NOV 2004)
L6 0 S L1

FILE 'HOME' ENTERED AT 12:02:26 ON 01 NOV 2004